Statins benefits

Robinson JG, Smith B, Maheshwari N, Schrott H, Pleiotropic effects of statins benefit beyond cholesterol reduction A meta-regression analysis. J Am Coll Cardiol 2005 46 1855-1862. 

Beyond Cholesterol Statin Benefits in Alzheimer s Disease... 

Much of the prior discussion has focused upon statin effects on cholesterol pathways. However, recent data suggest statin benefit in AD may occur via mechanisms completely independent of cholesterol lowering. For example, samples are known to modulate isoprenylation pathways and have potentially very potent anti-inflammatory activities [161]. Indeed, inhibition of proteins that are dependent upon isoprenylation, such as the Ras GT-Pase superfamily, has been suggested to be an import step in the inhibition of iNOS stimulated cytokine release [161]. In order to better understand... 

Soares HD, Sparks DL (2007) Beyond Cholesterol Statin Benefits in Alzheimer s Disease. 2 ... 

Several studies have investigated whether statins possess pharmacologic properties in addition to their LDL cholesterollowering effect that may confer additional benefits in IHD.24 These studies were prompted by evidence that patients with normal LDL cholesterol derived benefit from statins. Statins have been shown to modulate the following characteristics thought to stabilize atherosclerotic plaques and contribute to the cardiovascular risk reduction seen with these drugs ... 

There are now overwhelming data supporting the benefits of statins in patients with CAD in prevention of total mortality,... 

New substances of this family are in development, and we cannot exclude the possibility that oriented modifications of the molecules of SERMs, statins, or prostaglandin inhibitors will be able to enhance their effect on the breast or bone, maintaining equivalent power in their genuine indication. Knowing that a perfect multitasking molecule is unlikely, we can expect to obtain the maximal benefit from a single pharmacological intervention with substances with relevant added positive effects. 

Squamous cell carcinomas, 145 Standard of care doctrine, 187, 326 Start-ups, small, 130 "Statement on Benefit Sharing," 74 Statins, 91... 

Several approaches to statin side-chain intermediates have so far been discussed. Whereas these chemoenzymatic approaches provide clear benefits over the chemical processes, they do not harness the tme potential of biocatalysis as the biotransformations have simply been inserted into the existing chemical route. Wong and co-workers have developed a more biosynthetic-hke approach by using a mutant 2-deoxyiibose-5-phosphate aldolase (DERA)... 

Q80 Statins may be recommended to a 60-year-old asymptomatic male who is overweight, has a family history of coronary heart disease and is a smoker. The patient has a 10-year cardiovascular risk of 10% or more and is likely to benefit from statin treatment. 

Evidence-based pharmacotherapy provides a succinct appreciation of the benefits of a drug, but rarely takes into account the patient s quality of life. Eor instance, intensive statin therapy is recommended because it reduces the incidence of cardiovascular death (odds ratio 0.86), myocardial infarction (odds ratio 0.84), and stroke (odds ratio 0.82) however, the increased risks for any adverse event (odds ratio 1.44), for abnormalities on liver function testing (odds ratio 4.48), for elevations in CK (odds ratio 9.97) and for adverse events requiring discontinuation of therapy (odds ratio 1.28) are less often taken into account by the prescriber. This example emphasises that individualisation is of the utmost importance to keep an acceptable benefit/risk ratio (Clin Ther 2007 29 253-60). The benefits of evidence-based pharmacotherapy may be obtained whenever concordance/compliance of the patient is adequate. However, concordance rate is slightly higher than 30% for chronic conditions, such as hypertension (Curr Hypertens Rep 2007 9 184-9), indicating that the patient has to be educated about the use of drugs, and therapy has to be individualised. 

Statins are helpful in decreasing morbidity and mortality in people with high cholesterol, as well as individuals who have normal cholesterol but other risk factors for cardiovascular disease.66 It is estimated that these drugs decrease the risk of a major cardiac event by approximately 30 to 35 percent, although the benefits depend on the extent that cholesterol is reduced and the influence of other risk factors.91,95,126 Nonetheless, statins are now regarded as a mainstay in treating cardiovascular disease, and efforts are underway to expand the use of these medications and to explore the... 

Devroey D, Velkeniers B, Duquet W, Betz W. The benefit of fibrates in the treatment of bad HDL-C responders to statins . IntJ Cardiol. 2005 101 231-235. 

Wienbergen H, Gift AK, Schiele R, et al. MITRA PLUS Study Group. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003 92 285-288. 

There are now substantial data on the benefits of statins in people with diabetes. In the HPS, among 5963 individuals with diabetes, major vascular events were reduced by simvastatin from 25.1 % to 20.2% (P < 0.0001) (26). Among the subgroup of 2912 people with diabetes without prior vascular disease, the rate of major cardiovascular events was reduced from 13.5% to 9.3% (P = 0.0003). 

---